TREATMENT
Ifebemtinib plus garsorasib shows antitumor activity in KRAS G12C metastatic colorectal cancerA combination of ifebemtinib and garsorasib demonstrated encouraging antitumor activity in previously treated metastatic colorectal cancer patients with KRAS G12C mutations, according to results published in The Lancet Oncology. (The Manila Times)